Jaka jest cena za Novo Nordisk A/S (NOVO-B)

Cena za Novo Nordisk A/S (NOVO-B) wynosi $47.55

Jaka jest kapitalizacja rynkowa dla Novo Nordisk A/S (NOVO-B)

Kapitalizacja rynkowa dla Novo Nordisk A/S (NOVO-B) wynosi $211.25B

Zyski Novo Nordisk A/S (NOVO-B)

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
Eli Lilly and Company LLY.US	$33.59B	63.83%	US
Johnson & Johnson JNJ.US	$25.20B	22.88%	US
AbbVie Inc. ABBV.US	$8.70B	-57.58%	US
Roche Holding AG RO.SW	$21.39B	4.31%	CH
Merck & Co., Inc. MRK.US	$5.95B	-70.99%	US

Firma

Zyski

Różnica w zyskach

Kraj